Discovering drugs to treat coronavirus disease 2019 (COVID-19).
作者： Liying Dong , Shasha Hu , Jianjun Gao
关键词:
摘要: … Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease …
ceek.jp参考文章(20)
Andrea Savarino, Livia Di Trani, Isabella Donatelli, Roberto Cauda, Antonio Cassone, New insights into the antiviral effects of chloroquine Lancet Infectious Diseases. ,vol. 6, pp. 67- 69 ,(2006) , 10.1016/S1473-3099(06)70361-9
CM Chu, VCC Cheng, IFN Hung, MML Wong, KH Chan, KS Chan, RYT Kao, LLM Poon, CLP Wong, Y Guan, JSM Peiris, KY Yuen, None, Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. ,vol. 59, pp. 252- 256 ,(2004) , 10.1136/THORAX.2003.012658
Christopher M. Coleman, Jeanne M. Sisk, Rebecca M. Mingo, Elizabeth A. Nelson, Judith M. White, Matthew B. Frieman, Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. Journal of Virology. ,vol. 90, pp. 8924- 8933 ,(2016) , 10.1128/JVI.01429-16
Yousuke FURUTA, Takashi KOMENO, Takaaki NAKAMURA, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase Proceedings of the Japan Academy Series B: Physical and Biological Sciences. ,vol. 93, pp. 449- 463 ,(2017) , 10.2183/PJAB.93.027
Leen Delang, Rana Abdelnabi, Johan Neyts, Favipiravir as a potential countermeasure against neglected and emerging RNA viruses Antiviral Research. ,vol. 153, pp. 85- 94 ,(2018) , 10.1016/J.ANTIVIRAL.2018.03.003
Timothy P. Sheahan, Amy C. Sims, Sarah R. Leist, Alexandra Schäfer, John Won, Ariane J. Brown, Stephanie A. Montgomery, Alison Hogg, Darius Babusis, Michael O. Clarke, Jamie E. Spahn, Laura Bauer, Scott Sellers, Danielle Porter, Joy Y. Feng, Tomas Cihlar, Robert Jordan, Mark R. Denison, Ralph S. Baric, Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications. ,vol. 11, pp. 222- 222 ,(2020) , 10.1038/S41467-019-13940-6
Bin Su, Yin Wang, Ruifeng Zhou, Taiyi Jiang, Hongwei Zhang, Zaicun Li, An Liu, Ying Shao, Wei Hua, Tong Zhang, Hao Wu, Shenghua He, Lili Dai, Lijun Sun, Efficacy and Tolerability of Lopinavir/Ritonavir- and Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing, China Frontiers in Pharmacology. ,vol. 10, pp. 1472- ,(2019) , 10.3389/FPHAR.2019.01472
Markus Hoffmann, Hannah Kleine-Weber, Nadine Krüger, Marcel Müller, Christian Drosten, Stefan Pöhlmann, The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells bioRxiv. ,(2020) , 10.1101/2020.01.31.929042
Michelle L. Holshue, Chas DeBolt, Scott Lindquist, Kathy H. Lofy, John Wiesman, Hollianne Bruce, Christopher Spitters, Keith Ericson, Sara Wilkerson, Ahmet Tural, George Diaz, Amanda Cohn, LeAnne Fox, Anita Patel, Susan I. Gerber, Lindsay Kim, Suxiang Tong, Xiaoyan Lu, Steve Lindstrom, Mark A. Pallansch, William C. Weldon, Holly M. Biggs, Timothy M. Uyeki, Satish K. Pillai, First Case of 2019 Novel Coronavirus in the United States. The New England Journal of Medicine. ,vol. 382, pp. 929- 936 ,(2020) , 10.1056/NEJMOA2001191
Manli Wang, Ruiyuan Cao, Leike Zhang, Xinglou Yang, Jia Liu, Mingyue Xu, Zhengli Shi, Zhihong Hu, Wu Zhong, Gengfu Xiao, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. ,vol. 30, pp. 269- 271 ,(2020) , 10.1038/S41422-020-0282-0